Dupilumab Lessens Disease in COPD Patients
The monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD, according to investigators.
The monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD, according to investigators.
FDA approved a 300 mg single-dose pre-filled pen for Dupixent (dupilumab) to treat atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).